Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2009)American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 6251-6266

[3] Xu J(2009)Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 1227-1234

[4] Ward E(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550

[5] Azzoli CG(2008)Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543-3551

[6] Baker S(2004)Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589-1597

[7] Temin S(2000)Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095-2103

[8] Pao W(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-132

[9] Aliff T(2001)Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors Oncologist 6 363-373

[10] Brahmer J(2008)A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer Ann Oncol 19 939-945

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2009)American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 6251-6266

[3] Xu J(2009)Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 1227-1234

[4] Ward E(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550

[5] Azzoli CG(2008)Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543-3551

[6] Baker S(2004)Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589-1597

[7] Temin S(2000)Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095-2103

[8] Pao W(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-132

[9] Aliff T(2001)Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors Oncologist 6 363-373

[10] Brahmer J(2008)A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer Ann Oncol 19 939-945